

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



康臣 葯業集團有限公司
CONSUN PHARMACEUTICAL GROUP LIMITED

(Incorporated in the Cayman Islands with limited liability)

(Stock code: 1681)

NOTICE OF BOARD MEETING

The board of directors (the “**Board**”) of Consun Pharmaceutical Group Limited (the “**Company**”) hereby announces that a meeting of the Board will be held on Thursday, 30 March 2017 for the following purposes, among other things:

1. To consider and approve the audited consolidated financial statement of the Company and its subsidiaries (collectively the “**Group**”) for the year ended 31 December 2016 (the “**Annual Results**”);
2. To consider and to approve the draft announcement of the Annual Results of the Group to be published in accordance with the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited;
3. To consider the recommendation on the payment of a final dividend (if any) and the conditional special dividend of HK\$0.1 per share as proposed in the Company’s announcement dated 6 February 2017;
4. To consider matters related to the convening of the forthcoming annual general meeting of the Company; and
5. To consider and approve other matters, if any.

By order of the Board of
Consun Pharmaceutical Group Limited
AN Yubao
Chairman

Hong Kong, 14 March 2017

As at the date of this announcement, the Board comprises Mr. AN Yubao, Ms. LI Qian and Professor ZHU Quan as executive Directors; Mr. WANG Shunlong and Mr. LIN Sheng as non-executive Directors; Mr. SU Yuanfu, Mr. FENG Zhongshi and Ms. CHENG Xinxin as independent non-executive Directors.